The cell and gene therapy boom is running into its manufacturing bill. Traditional production remains manual and expensive, which makes the ROI for many therapies murky at best. Venture funding in the sector has plunged more than 80% from its 2021 peak.
Cellares is betting the path forward is industrial. The South San Francisco company raised $257 million in Series D funding today to build automated “Smart Factories” that it claims can slash the capital and labor costs choking cell…
